Further support for this conclusion comes from the observation that RIPK1 and RIPK3 expression in the NCI-60 human cancer cell panel does not correlate with cellular response to anticancer drugs (Supplementary Table S2).61 Hence, current chemotherapeutic agents appear to preferentially activate other cell death pathways and are ineffective inducers of necroptosis. Here, RIPK1 is linked to cancer.